Two years in­to an R&D over­haul, GSK plans $250M lab project near Philly for an­oth­er mi­gra­tion of US staffers

Glax­o­SmithK­line set out to com­plete­ly over­haul its US R&D or­ga­ni­za­tion in late 2014, ax­ing hun­dreds of staffers in its long­time drug in­ves­ti­ga­tion cen­ter in Re­search Tri­an­gle Park to counter the slug­gish progress of its pipeline. The move by CEO An­drew Wit­ty set in mo­tion a se­ries of re­struc­tur­ing waves that have had a pro­found im­pact on its re­search groups, now cen­tered in Philadel­phia and Steve­nage in the UK.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.